Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Oct 1;81(14):1197-204.
doi: 10.1212/WNL.0b013e3182a6cb5c. Epub 2013 Aug 30.

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica

Affiliations
Comparative Study

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica

Yujuan Jiao et al. Neurology. .

Abstract

Objective: To 1) determine, using contemporary recombinant antigen-based assays, the aquaporin-4 (AQP4)-immunoglobulin G (IgG) detection rate in sequential sera of patients assigned a clinical diagnosis of neuromyelitis optica (NMO) but initially scored negative by tissue-based indirect immunofluorescence (IIF) assay; and 2) evaluate the impact of serostatus on phenotype and outcome.

Methods: From Mayo Clinic records (2005-2011), we identified 163 patients with NMO; 110 (67%) were seropositive by IIF and 53 (33%) were scored seronegative. Available stored sera from 49 "seronegative" patients were tested by ELISA, AQP4-transfected cell-based assay, and in-house fluorescence-activated cell sorting assay. Clinical characteristics were compared based on final serostatus.

Results: Thirty of the 49 IIF-negative patients (61%) were reclassified as seropositive, yielding an overall AQP4-IgG seropositivity rate of 88% (i.e., 12% seronegative). The fluorescence-activated cell sorting assay improved the detection rate to 87%, cell-based assay to 84%, and ELISA to 79%. The sex ratio (female to male) was 1:1 for seronegatives and 9:1 for seropositives (p < 0.0001). Simultaneous optic neuritis and transverse myelitis as onset attack type (i.e., within 30 days of each other) occurred in 32% of seronegatives and in 3.6% of seropositives (p < 0.0001). Relapse rate, disability outcome, and other clinical characteristics did not differ significantly.

Conclusions: Serological tests using recombinant AQP4 antigen are significantly more sensitive than tissue-based IIF for detecting AQP4-IgG. Testing should precede immunotherapy; if negative, later-drawn specimens should be tested. AQP4-IgG-seronegative NMO is less frequent than previously reported and is clinically similar to AQP4-IgG-seropositive NMO.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flowchart of the NMO cohort
Of 163 patients whose serum was tested (one or more sequential specimens) by tissue-based IIF, 53 were scored negative. For 49 with available stored specimens, 30 (61%) were found to be AQP4-IgG positive when retested by recombinant antigen–based assays. AQP4 = aquaporin-4; CBA = cell-based assay; FACS = fluorescence-activated cell sorting assay; IgG = immunoglobulin G; IIF = indirect immunofluorescence; NMO = neuromyelitis optica; QNS = insufficient serum for further evaluation.
Figure 2
Figure 2. Kaplan-Meier estimates of time to motor and visual disability by AQP4-IgG serostatus
(A) Years from onset to use of a cane (p = 0.43): at 5 years after onset, 28% of seronegative patients and 22% of seropositive patients were expected to need a cane to walk (EDSS score 6). (B) Years from onset to need for a wheelchair (p = 0.10): at 5 years after onset, no seronegative and 8% of seropositive patients were expected to be unable to walk and to need a wheelchair (EDSS score 8). (C) Years from onset to legal blindness in at least one eye (p = 0.34): at 5 years after onset, 57% of seronegative and 41% of seropositive patients were expected to be legally blind in at least one eye. (D) Years from onset to legal blindness in both eyes (p = 0.64): at 5 years after onset, 5% of seronegative and 9% of seropositive patients were expected to be legally blind in both eyes. (E) Years from onset to use of a cane for seropositive NMO (p = 0.07): at 5 years after disease onset, 36% TM-onset vs 14% ON-onset patients were expected to need a cane. (F) Years from onset to legal blindness in at least one eye for seropositive NMO (p = 0.09): at 5 years after disease onset, 39% of TM-onset vs 55% of ON-onset patients were expected to be legally blind in at least one eye. EDSS score 6 = intermittent or unilateral assistance (canes, crutches, or braces) required to walk 100 m with or without resting; EDSS 8 = restricted to bed or chair or perambulated in wheelchair but may be out of bed much of day, retains many self-care functions, generally has effective use of arms; legal blindness = sustained visual acuity of 20/200 or less with best correction possible for more than 6 months. AQP4 = aquaporin-4; EDSS = Expanded Disability Status Scale; IgG = immunoglobulin G; NMO = neuromyelitis optica; ON = optic neuritis; TM = transverse myelitis.

Comment in

References

    1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107–1114 - PubMed
    1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–815 - PubMed
    1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106–2112 - PubMed
    1. Hayakawa S, Mori M, Okuta A, et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 2008;196:181–187 - PubMed
    1. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009;66:1134–1138 - PubMed

Publication types

LinkOut - more resources